aid: abtis2772
name: AbTis
description: >-
  AbTis Co., Ltd. (앱티스) is a South Korean biotechnology company founded in 2016 and headquartered in
  Yongin-si, Gyeonggi-do, inside the Dong-A Socio Holdings R&D Center. It develops AbClick, a
  third-generation site-selective antibody conjugation platform that attaches payloads to the Fc
  Lys248 residue of native IgG antibodies with no enzyme and no Fc engineering, giving a controlled
  drug-to-antibody ratio and batch-to-batch consistency across ADC, DAC, AOC, ARC, ISAC and
  dual-payload designs. AbTis licenses the platform, runs collaborative research and fee-for-service
  ADC development, and advances its own pipeline led by AT-211, a Claudin 18.2-targeting MMAE ADC.
  Acquired by Dong-A ST in 2023, it now operates as that company's ADC-specialised subsidiary. Its
  product is licensed chemistry and drug intellectual property, not software: it runs no developer
  program, public API, SDK or machine-readable contract.
url: https://raw.githubusercontent.com/api-evangelist/abtis2772/refs/heads/main/apis.yml
image: https://abtis.co.kr/assets/favicon/favicon-96x96.png
x-type: company
x-source: harvest:secondary-market
x-harvest-source-url: https://equityzen.com/company/abtis2772/
x-tier: stub
x-tier-reason: harvest
x-legal-name: AbTis Co., Ltd.
x-parent-company: Dong-A ST
x-api-posture: no-product-api
x-api-posture-basis: observed
x-api-posture-note: >-
  AbTis licenses ADC linker chemistry and sells laboratory services; its only web property is a
  gnuboard5 corporate marketing site at abtis.co.kr whose entire navigation is Company, Science,
  Business and News. No developer portal, API reference, OpenAPI, GraphQL, AsyncAPI, MCP server or
  agent card exists on any host it controls, no package named abtis is published to npm or PyPI, and
  github.com/abtis is an unrelated individual account, not a company organization.
specificationVersion: '0.20'
created: '2026-09-06'
modified: '2026-09-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Antibody-Drug Conjugates
- Bioconjugation
- Drug Discovery
- Oncology
- Life Sciences
- Healthcare
- South Korea
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/abtis2772-domain-security.yml
- type: LLMsTxt
  url: llms/abtis2772-llms.txt
- type: Website
  url: https://abtis.co.kr/en/
- type: SecondaryMarket
  url: https://equityzen.com/company/abtis2772/
- type: About
  url: https://abtis.co.kr/en/company/overview.php
- type: Contact
  url: https://abtis.co.kr/en/company/contact.php
- type: PressReleases
  url: https://abtis.co.kr/en/pr-center/press-release.php
x-enrichment:
  date: '2026-09-06'
  status: minimal
  artifacts_added: 3
  pass: local-v3
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    AbTis sells ADC linker chemistry — AbClick platform licences, collaborative research and
    fee-for-service conjugation work — so there is no software product to expose: its only web
    property is a gnuboard5 corporate site whose entire navigation is Company, Science, Business and
    News, and behind the site's CUPID JavaScript cookie challenge (which answers HTTP 200 with a
    ~780-byte script on every path, then the real status on the cookied retry) /openapi.json,
    /swagger.json, /api-docs, /graphql, /llms.txt, /robots.txt, /sitemap.xml and all eight
    /.well-known/ paths return a genuine Apache 404.
  evidence:
  - url: https://abtis.co.kr/en/
    status: 200
  - url: https://abtis.co.kr/openapi.json
    status: 404
  - url: https://abtis.co.kr/swagger.json
    status: 404
  - url: https://abtis.co.kr/graphql
    status: 404
  - url: https://abtis.co.kr/.well-known/agent-card.json
    status: 404
  - url: https://abtis.co.kr/.well-known/api-catalog
    status: 404
  - url: https://abtis.co.kr/llms.txt
    status: 404
  - url: https://www.abtis.co.kr/openapi.json
    status: 403
  - url: https://registry.npmjs.org/-/v1/search?text=abtis
    status: 200
  checked: '2026-09-06'